Latest Articles
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3 - Fierce Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3 Fierce Biotech
Published: May 23, 2025, 1:22 p.m.
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment - TipRanks
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment TipRanks
Published: May 23, 2025, 10:59 a.m.
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 - Stock Titan
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 Stock Titan
Published: May 22, 2025, 9:05 p.m.
Navigating complexities of polymorphic microbiomes in endometrial cancer - Nature
Navigating complexities of polymorphic microbiomes in endometrial cancer Nature
Published: May 22, 2025, 6:42 p.m.
ASCO 2025: A Preview of Advancements in Endometrial Cancer - Medscape
ASCO 2025: A Preview of Advancements in Endometrial Cancer Medscape
Published: May 21, 2025, 5:15 p.m.
PORTEC-4a Study Supports Personalized Radiotherapy in Early Endometrial Cancer - Medical Dialogues
PORTEC-4a Study Supports Personalized Radiotherapy in Early Endometrial Cancer Medical Dialogues
Published: May 21, 2025, 3 p.m.
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - OncLive
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer OncLive
Published: May 21, 2025, 2:09 p.m.
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ - openPR.com
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ openPR.com
Published: May 21, 2025, 12:38 a.m.
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Barchart.com
Published: May 20, 2025, 11:32 p.m.
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification - Nature
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification Nature
Published: May 20, 2025, 7:23 p.m.
Link copied to clipboard!